Poster Presentation 4th Metabolic Diseases; Breakthrough Discoveries in Diabetes & Obesity Meeting 2024

Reversing GLP-1R Agonist Resistance to Turbocharge Metabolic Disease Treatment (#163)

Callen C Goldsmith 1 , Cait A Beddows 1 , Feiyue Shi 1 , Amy A Worth 2 , Olivia Wood 1 , Rui Qi Teo 1 , Marie H Solheim 3 , Frank Reimann 4 , Jens C Bruning 3 , Simon M Luckman 2 , Garron T Dodd 1
  1. Anatomy and Physiology, The University of Melbourne, Parkville, VICTORIA, Australia
  2. Division of Diabetes, Endocrinology and Gastroenterology, School of Medicine, University of Manchester, Manchester, United Kingdom
  3. Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Colonge, Germany
  4. Institute of Metabolic Science & MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, United Kingdom
Publish consent withheld
  1. le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet 389, 1399-1409 (2017). https://doi.org/https://doi.org/10.1016/S0140-6736(17)30069-7
  2. Pi-Sunyer, X. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine 373, 11-22 (2015). https://doi.org/10.1056/NEJMoa1411892
  3. Mosikian, A. A., Golikova, T. I., Martjanova, M. V. & Babenko, A. Y. Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes. Future Sci OA 8, Fso779 (2022). https://doi.org/10.2144/fsoa-2021-0070
  4. Fansa, S. et al. FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist. J Endocr Soc 7 (2023).
  5. Ohsugi, M., Eguchi, K., Thietje Mortensen, J., Yamamoto, Y. & Ueki, K. Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G). Diabetes Research and Clinical Practice 203, 110841 (2023). https://doi.org/https://doi.org/10.1016/j.diabres.2023.110841
  6. Rodriguez, P. et al. Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study. (2023).
  7. Wharton, S. et al. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obesity Science & Practice 6, 439-444 (2020). https://doi.org/https://doi.org/10.1002/osp4.420
  8. White, G. E. et al. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study. Obesity (Silver Spring) 31, 537-544 (2023). https://doi.org/10.1002/oby.23622